A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether chemical pleurodesis is superior to catheter drainage or pleuroperitoneal shunts (PPS) in the management of patients with pleural effusions. Overall 161 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that chemical pleurodesis is superior to chronic catheter drainage and PPS in terms survival length and mortality rates but in patients with trapped lung syndrome chronic intrapleural catheter placement is indicated. Six studies reported patient outcomes after treatment with chemical pleurodesis. They report high success rates (89.4%) and low mortality rates (2%) without any need to convert to open thoracotomy. Mean hospital stay of 2.33 days, complication rates of 16.5% and mean survival length of 23.8"16.3 months were observed. Five studies managed malignant pleural effusions (MPEs) using chronic indwelling catheters. They reported mean survival length of 126 days. Symptomatic relief was achieved in 94.2% of patients. There was a significant reduction in the Medical Research Council dyspnoea score (3.0-1.9, P-0.001) and despite complication rates of 22%, comparable mortality rates (7.5%) were observed. Even in patients with trapped lung syndrome, mean survival length was 125 days with symptomatic improvement being achieved in 90.9% of patients. Three studies treated MPEs using PPSs. Mean hospital stay was 6.2 days (range 2-26) with a mean survival length of 11 months. Pleurodesis success rates varied from 57.1% to 95% with a complication rate of 14.8%. PPSs were shown to produce lower success rates (57.1% vs. 92.3%), shorter survival lengths (4.3"1.9 vs. 6.7"2.1 months) and higher complication rates (14.3% vs. 2.8%) than talc pleurodesis. Overall, chemical pleurodesis is the optimal treatment option for MPE with use of chronic intrapleural catheters reserved in cases where talc pleurodesis is not possible.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients with malignant pleural effusion (MPE)x is wchemical pleurodesisx superior to wcatheter drainage or pleuroperitoneal shuntsx in terms of weffusion recurrence, survival and morbidityx.
Clinical scenario
You review a 68-year-old female with a known diagnosis of Butchart stage II malignant pleural mesothelioma. She has worsening dyspnoea and right large effusion on chest radiogram. Cytology confirms the diagnosis. You question whether chemical pleurodesis would be the best management option to prevent effusion recurrence. You resolve to check the literature. *Corresponding author. Tel.yfax: q44-75-15542899. E-mail address: marco.scarci@mac.com (M. Scarci).
Search strategy
Medline was searched from 1948 to January 2011 using the OVID SP interface wexp MesotheliomayOR mesothelioma.mp.x AND wpleural effusion.mp.OR exp Pleural Effusionyx AND wexp Chest TubesyOR exp Drainagey OR exp ThoracostomyyOR chest drain.mp. OR surgery.mp. OR exp General SurgeryyOR VATS.mpx.
Search outcome
One hundred and sixty-one papers were found using the reported search. From these 14 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 . In addition, the reference list of each paper was searched.
Results
Management of malignant pleural effusion (MPE) using chemical pleurodesis involves the use of various sclerosing agents including talc, antibiotics, chemotherapy or bacterial products, which can all affect patient outcomes w16x. I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) (Continued on next page) I. Zahid et al. / Interactive CardioVascular and Thoracic Surgery 12 (2011) Six studies managed MPE using chemical pleurodesis. Barbetakis et al. w2x used video-assisted thoracoscopic surgery (VATS) talc insufflation to treat MPE and reported pleurodesis success rate of 85%. Mean duration of talc pleurodesis was 26 min with mean chest drain duration of six days. In-patient mortality rate was low (2%) but a high complication rate (16.5%) was observed. Similarly, Kolschmann et al. w3x managed MPE using thoracoscopic talc poudrage and reported high successful pleurodesis rates at both one month (89.4%) and six months (82.6%) postoperative. Mortality rates rose from 16.7% at 30 days postoperative to 54.9% at six months. In 2005, Aelony and Yao w4x administered thoracoscopic talc poudrage to manage MPE and found mean ("S.D.) survival lengths of 23.8 ("16.3) months. Mean hospital stay was 3.9 days with median chest tube drainage of 2.8 days. Symptoms improved in all patients postoperative but effusions recurred in 19% of cases.
Yildrim et al. w5x managed MPE using oxytetracycline (OT) and compared outcomes with standard and rapid fractionated protocols. They found complete effusion resolution rates of 83% and 50% using the rapid and standard protocols, respectively. Longer hospital stays (8.33 vs. 2.33 days, P-0.001), greater drainage duration (7.00 vs. 1.87 days, P-0.001) and higher costs ($740 vs. $200, P-0.001) were observed with standard protocol compared to the rapid fractionated approach. Rahman et al. w6x randomised patients to receive lipoteichoic acid-T (LTA-T)-mediated pleurodesis. They reported high pleurodesis success rate (92%) with significant reduction in pleural fluid production (1244-394 ml, Ps0.028). Senyigit et al. w7x managed mesothelioma-associated effusions using OT (ns59), Cornyebacterium parvum (CP) (ns29) or nitrogen mustard (NT) (ns29) instillation. Success rates were lowest with NT compared to OT and CP, respectively Three studies treated MPE using pleuroperitoneal shunts (PPS). Genc et al. w13x conducted 160 PPS and reported a pleurodesis success rate of 95%. Mean hospital stay was 6.2 days with a complication rate of 14.8%. Mean survival length was 7.7 months with a greater benefit observed in patients with mesothelioma-associated effusions (10.1 months). Tsang et al. w14x placed 16 PPS and reported mean hospital stay of 6.9 days. Drain shunt remained functional for a mean 8.6 months and led to an overall survival length of 11 months. More recently, Schulze et al. w15x compared the effectiveness of PPS (ns14) to talc pleurodesis (ns105) in managing MPEs. Longer operative times (55 vs. 35 min), higher complication rates (14.3% vs. 2.8%) but shorter hospital stays (8.1 vs. 10.7 days) were reported with PPS than talc pleurodesis. PPS also had lower success rates (57.1% vs. 92.3%) and shorter survival lengths (4.3"1.9 vs. 6.7"2.1 months) than talc pleurodesis.
Clinical bottom line
Currently, there is no consensus on whether patients with MPEs should undergo chemical pleurodesis or chronic catheter drainage. The studies above have shown that chemical pleurodesis produces longer survival and lower mortality rates making it a preferable treatment option to chronic catheter drainage or PPS in patients with MPEs. However, in cases where chemical pleurodesis is not possible, such as trapped lung syndrome, chronic catheter drainage should be the treatment option of choice.
